The stock of Harvard Bioscience (HBIO, Financial) recently saw a significant increase, with its price rising by 5.02% to $2.51 per share. The stock's trading volume reached 59,525 shares, with a turnover rate of 0.14% and a price volatility of 5.44%.
Recent financial reports revealed that Harvard Bioscience generated a revenue of $21.97 million, although it registered a net loss of $4.80 million, leading to an earnings per share (EPS) of -$0.11. The company's gross profit stood at $11.43 million, and it has a price-to-earnings (P/E) ratio of -7.56.
Analyst ratings are favorable for Harvard Bioscience, with all participating institutions recommending a "buy." No institution suggested holding or selling the stock.
Within the broader medical equipment industry, which saw an overall increase of 1.09%, Harvard Bioscience's peers such as Nexgel Inc C/Wts 01/12/2026 (To Pur Com), Microbot Medical Inc., and Nexgel, Inc demonstrated notable gains. Companies like Avinger, Inc. and Bionano Genomics, Inc. showed significant trading activity with turnover rates of 5.11%, 4.10%, and 3.06% respectively. Stocks with high price volatility included Nexgel Inc C/Wts 01/12/2026 (To Pur Com), Bionano Genomics, Inc., and others.
Harvard Bioscience Inc specializes in developing, manufacturing, and selling technology and specialized products that support drug development's fundamental research, discovery, and pre-clinical testing. With operations in North America, Europe, and China, the company provides scientific instruments critical for life science research to a global customer base through direct sales and distribution channels. Its major product brands include Harvard Apparatus, DSI, Buxco, Biochrom, and others, with a majority of its revenue originating from the United States.
